Compare Centene Corp (CNC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Revvity Inc — how do they compare? Centene Corp trades at $65 (market cap $32.05B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Centene Corp is far larger — about 2.5× Revvity Inc's market cap, and Revvity Inc pays a 0.24% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | RVTY | |
|---|---|---|
Market Cap | $32.05B | $12.91B |
Sector | Health | Technology |
52-Week High | $68.72 | $117.75 |
52-Week Low | $26.17 | $82.26 |
Enterprise Value | $21.10B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $67.35, up 1.19% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock has beaten earnings estimates in recent quarters, including Q2 2026 EPS of $2.51 versus $1.09 expected, and shows robust cash flow trends with 2025 net cash flow of $3.94 billion. Recent news highlights margin recovery and raised 2026 guidance, reinforcing positive momentum.
The outlook remains favorable given valuation discounts (P/E of 8.06, P/S of 0.16) and analyst consensus price target of $71.00, though risks include negative net income margins and Medicaid membership volatility. Upside potential hinges on execution of cost controls and premium growth in government-sponsored health plans.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
